SCHEMBL30462016

SCHEMBL30462016

CN1CCc2cc(C#N)ccc2C1=O

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 3/20 0.68
HRH3 Q9Y5N1 7/20 0.50
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
HTR2A P28223 1/20 0.48
HTR2C P28335 1/20 0.48
HTR2B P41595 1/20 0.48
DRD2 P14416 3/20 0.47
DRD3 P35462 3/20 0.47
DRD4 P21917 1/20 0.47
KCNH2 Q12809 1/20 0.46
CASP3 P42574 1/20 0.45
LRRK2 Q5S007 1/20 0.45
PRMT5 O14744 1/20 0.45
WDR77 Q9BQA1 1/20 0.45
OPRD1 P41143 1/20 0.44
CYP11B1 P15538 1/20 0.44
CYP11B2 P19099 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26627782 1.00 GRM5 (0.68) GRM5HRH3MEN1KMT2AHTR2A
SCHEMBL10163701 0.88 GRM5 (0.52) GRM5HRH3MEN1KMT2AHTR2A
SCHEMBL30425281 0.88 GRM5 (0.52) GRM5HRH3MEN1KMT2AHTR2A
SCHEMBL17519980 0.84 CYP11B1 (0.52) GRM5HRH3HTR2AHTR2CHTR2B
SCHEMBL30462027 0.81 GRM5 (0.46) GRM5HRH3HTR2AHTR2CHTR2B
SCHEMBL26627833 0.81 GRM5 (0.46) GRM5HRH3HTR2AHTR2CHTR2B
SCHEMBL504663 0.81 GRM5 (1.00) GRM5MEN1KMT2A
SCHEMBL7368335 0.78 DRD2 (0.50) GRM5HRH3MEN1KMT2ADRD2
SCHEMBL424393 0.77 GRM5 (0.57) GRM5MEN1KMT2AHTR2AHTR2C
SCHEMBL18053937 0.77 GRM5 (0.57) GRM5MEN1KMT2AOPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4741386-A1 PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2026-05-13 EP disclosed
US-20250289799-A1 PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF JIANGSU YAHONG MEDITECH CO., LTD. (CN) 2025-09-18 US disclosed
EP-4516779-A1 PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2025-03-05 EP disclosed
WO-2025007777-A1 PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 江苏亚虹医药科技股份有限公司 2025-01-09 WO disclosed
CN-118660872-A Pyrimidine compound, preparation method and medical application thereof 江苏亚虹医药科技股份有限公司 2024-09-17 CN disclosed
CN-116496252-A Pyrimidine compound, preparation method and medical application thereof 江苏亚虹医药科技股份有限公司 2023-07-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250289799-A1 PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF USP1, UPP1, UFL1 GRM5 3788/4885HRH3 3771/4885MEN1 1607/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.